|Articles|November 6, 2012

NovaBay receives $2.6M to advance Aganocide research

NovaBay Pharmaceuticals has received $2.6 million from partner Galderma for the clinical advancement of NovaBay’s “non-antibiotic, anti-infective” Aganocide compound NVC-422, a topical formulation for impetigo treatment.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME